Clinical trials: Botulinum toxin type A
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan
Interstitial Cystitis
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
The purpose of this research study is to identify the optimal usage of Onabotulinumtoxin A in interstitial cystitis. Onabotulinumtoxin A, more commonly known by the trade name Botox®, is a medication that comes from the bacteria…
- Trial name
- NCT02297100
- Testing
- Onabotulinumtoxin A, injections upper aspect of trigone of urinary bladder, injections on posterior bladder wall excluding the trigone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Forehead Lines
A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05152576
- Testing
- OnabotulinumtoxinA X
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- Allergan
Hemifacial Spasm
Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients
A 50-Week Prospective, Double-Blinded, Randomized, Cross-over design in Multicenter Study of 100 unit of Abobotulinum Toxin Type A (Dysport®) versus 33.33 unit of Neubotulinum Toxin Type A (Neuronox®) Injection for Hemifacial…
- Trial name
- DNHFS (NCT04589364)
- Testing
- Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)
- Where
- 4 sites in Thailand
- Volunteers
- 107 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Keloid
Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids
Keloids are a common form of hypertrophic scars that by definition last beyond 6 months and grow beyond the site of initial injury.
- Trial name
- NCT05330078
- Testing
- Botulinum toxin type A, Vehicle
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Hyperhidrosis
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in…
- Trial name
- NCT01128738
- Testing
- GSK1358820
- Where
- 14 sites in Japan
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Sleep-Disordered Breathing
Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders
This proof-of-concept study is to assess the potential benefit of botulinum toxin for patients with sleep-related breathing disorders.
- Trial name
- Snoring (NCT00773591)
- Testing
- NT 201, a Botulinum neurotoxin type A, free of complexing proteins
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Lines
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
This study aims to look at patient and physician satisfaction of long term Glabellar lines (GL) treatment with Dysport in a real life setting.
- Trial name
- APPEAL (NCT02353897)
- Where
- 14 sites in Australia, Brazil and 6 more
- Volunteers
- 150 people
- Sponsor
- Ipsen
Temporomandibular Joint Disorders, Bruxism
Botox for Treatment of TMJ Disorder With Bruxism
Hypothesis: Myofascial temporomandibular joint disorder and related symptoms are associated with mandibular condyle and temporal fossa overloading secondary to temporalis and masseter muscle hyperactivity and spasm This study…
- Conditions
- Temporomandibular Joint Disorders, Bruxism, Temporomandibular Joint Dysfunction Syndrome, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint
- Trial name
- TMJ (NCT02202070)
- Testing
- onabotulinumtoxinA
- Where
- United States
- Sponsor
- Washington University School of Medicine
Dystonia, Dystonic Disorder
Meditoxin® Treatment in Patients With Cervical Dystonia
To determine the efficacy and safety of Meditoxin in subjects with cervical dystonia compared with placebo (normal saline)
- Trial name
- NCT03232320
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Medy-Tox
Buerger Disease, Raynaud Syndrome
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease.
- Trial name
- BETOX (NCT05698979)
- Testing
- BOTOX INJECTION
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Toulouse
Stroke, Spasticity as Sequela of Stroke
Effect of ESWT Applied After Botulinum Toxin Injection on Ankle Spasticity in Stroke Patients.
Stroke is the second most common cause of death and the third most important cause of disability worldwide, with an annual death rate of 5.5 million.
- Trial name
- NCT06126523
- Testing
- Radial Extracorporeal Shock Wave Therapy ONCE, Radial Extracorporeal Shock Wave Therapy TWİCE
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Saglik Bilimleri Universitesi
Overactive Bladder
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX
- Trial name
- NCT03371342
- Testing
- Meditoxin, Botox
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Medy-Tox
Blepharospasm
Blepharospasm Short Interval
The objective of this Phase II study is to show that pre-treated patients with BEB with the need of shortened injection intervals achieve an improved and stable quality of life level if they receive repeated NT 201 injections at…
- Trial name
- NCT00507637
- Testing
- NT 201
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cerebrovascular Accident
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
The aims of this study were to compare the injection locations of key spastic muscles on upper extremity by three different guidance localization methods ( surface anatomy landmark, ultrasonography, electric stimulation) and the…
- Trial name
- NCT02557737
- Testing
- Botulinum Toxin Type A
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Upper Limb Spasticity
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to…
- Trial name
- DIRECTION (NCT04936542)
- Testing
- AboBoNT-A, OnaBoNT-A
- Where
- 76 sites in United States, Canada and 2 more
- Volunteers
- 464 people
- Sponsor
- Ipsen
Healthy
Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers
To determine the pharmacodynamic and safety of MBA-P01 in Healthy Male Volunteers
- Trial name
- NCT03547141
- Testing
- MBA-P01, BOTOX
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Stroke
Effects of Combined Treatment by Botulinum Toxin and Lokomat® on Walking Ability in Chronic Stroke
75% patients in the chronic phase of a stroke keep walking disabilities. Focal spasticity in the paretic lower limb frequently causes these walking disabilities, and the gold standard treatment is intramuscular injection of…
- Trial name
- Lokomat (NCT03659266)
- Testing
- Robotic walking rehabilitation by Lokomat®, Conventional walking rehabilitation
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.